QualityStocks would like to highlight Cannabis Science, Inc. (OTCBB: CBIS). The company is at the forefront of medical marijuana research and development. Cannabis Science works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.
In the company’s news yesterday,
Cannabis Science Inc. announced that Dr. Ben Johnson, Dr. Allan Shackleford, and Dr. William Courtney have all accepted membership on the company’s recently formed Scientific Advisory Board. Already serving on the board are Dr. Mitch Earlywine, Ph.D. and Dr. Ritchard Fishman, M.D. The addition of several prominent scientists and physicians is expected to help hasten the company’s FDA submissions.
Dr. Ben Johnson is a complementary and alternative medicine physician, with a degree in Osteopathy in addition to M.D. and N.M.D. degrees. He is the founder and previous director of the Immune Recovery Clinic in Atlanta, Georgia. He served in Vietnam, and was a flight surgeon in the Army Reserve for many years. He was also a Senior Aviation Medical Examiner for the FAA for 12 years. Dr. Johnson is currently the owner of Dr. Ben Johnson Services, LLC, where he consults with patients and health care professionals across the world, emphasizing complementary oncology and natural health care.
Dr. Alan Shackleford, a Denver physician, is a graduate of the University of Heidelburg School of Medicine, with an extensive background in clinical medicine, nutrition support, metabolism analysis, micro-vascular surgical techniques, and stress management techniques in the treatment of obesity and performance anxiety. Dr. Shackleford is also an instructor in genetics at the University of Maryland, and has lectured at Harvard Medical School in clinical training for behavioral medicine.
Dr. William Courtney, in addition to holding a B.S. in Microbiology and M.D. degree, has a Post Doctorate in Forensic Examination and Forensic Medicine. He is a member of the International Cannabinoid Research Society, the International Association of Cannabis as Medicine, and the Society of Clinical Cannabis. Dr. Courtney teaches Continuing Medical Education (CME) courses in clinical cannabis, and a Survey Course on Endogenous Cannabinoid System, and hosted the Second International CB2 Conference in California.
Cannabis Science president and CEO, Dr. Robert Melamede, Ph. D., commented on the new board members. “We have been enormously gratified by the very positive reaction to the company’s plans by those who are most familiar with the need for medical cannabis products. The fact that so many prominent experts understand the importance of what we are doing and support our efforts shows that we are on the right path. We are putting together a very powerful team and with their help we will successfully blend the revolutionary power of capitalism with activism moving the company forward.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.